223 related articles for article (PubMed ID: 28463826)
1. A case controlled study examining the bladder microbiome in women with Overactive Bladder (OAB) and healthy controls.
Curtiss N; Balachandran A; Krska L; Peppiatt-Wildman C; Wildman S; Duckett J
Eur J Obstet Gynecol Reprod Biol; 2017 Jul; 214():31-35. PubMed ID: 28463826
[TBL] [Abstract][Full Text] [Related]
2. Urinary Microbiome and Psychological Factors in Women with Overactive Bladder.
Wu P; Chen Y; Zhao J; Zhang G; Chen J; Wang J; Zhang H
Front Cell Infect Microbiol; 2017; 7():488. PubMed ID: 29230385
[No Abstract] [Full Text] [Related]
3. Age, menopausal status and the bladder microbiome.
Curtiss N; Balachandran A; Krska L; Peppiatt-Wildman C; Wildman S; Duckett J
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():126-129. PubMed ID: 29936400
[TBL] [Abstract][Full Text] [Related]
4. Interplay between bladder microbiota and overactive bladder symptom severity: a cross-sectional study.
Li K; Chen C; Zeng J; Wen Y; Chen W; Zhao J; Wu P
BMC Urol; 2022 Mar; 22(1):39. PubMed ID: 35305613
[TBL] [Abstract][Full Text] [Related]
5. Vaginal estrogen therapy is associated with increased Lactobacillus in the urine of postmenopausal women with overactive bladder symptoms.
Thomas-White K; Taege S; Limeira R; Brincat C; Joyce C; Hilt EE; Mac-Daniel L; Radek KA; Brubaker L; Mueller ER; Wolfe AJ
Am J Obstet Gynecol; 2020 Nov; 223(5):727.e1-727.e11. PubMed ID: 32791124
[TBL] [Abstract][Full Text] [Related]
6. A blinded observational cohort study of the microbiological ecology associated with pyuria and overactive bladder symptoms.
Gill K; Kang R; Sathiananthamoorthy S; Khasriya R; Malone-Lee J
Int Urogynecol J; 2018 Oct; 29(10):1493-1500. PubMed ID: 29455238
[TBL] [Abstract][Full Text] [Related]
7. Differences in the Urinary Microbiome of Patients with Overactive Bladder Syndrome with and without Detrusor Overactivity on Urodynamic Measurements.
Javan Balegh Marand A; Baars C; Heesakkers J; van den Munckhof E; Ghojazadeh M; Rahnama'i MS; Janssen D
Life (Basel); 2023 May; 13(5):. PubMed ID: 37240844
[TBL] [Abstract][Full Text] [Related]
8. The gut, vaginal, and urine microbiome in overactive bladder: a systematic review.
Sze C; Pressler M; Lee JR; Chughtai B
Int Urogynecol J; 2022 May; 33(5):1157-1164. PubMed ID: 35237854
[TBL] [Abstract][Full Text] [Related]
9. Unraveling the impact of
Zhou Z; Qiu Y; Li K; Sun Q; Xie M; Huang P; Yu Y; Wang B; Xue J; Zhu Z; Feng Z; Zhao J; Wu P
Front Cell Infect Microbiol; 2022; 12():1030315. PubMed ID: 36452303
[TBL] [Abstract][Full Text] [Related]
10. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
11. Correlation between psychological stress levels and the severity of overactive bladder symptoms.
Lai H; Gardner V; Vetter J; Andriole GL
BMC Urol; 2015 Mar; 15():14. PubMed ID: 25887525
[TBL] [Abstract][Full Text] [Related]
12. The influence of gut microbiome on progression of overactive bladder symptoms: a community-based 3-year longitudinal study in Aomori, Japan.
Okuyama Y; Okamoto T; Sasaki D; Ozaki K; Songee J; Hatakeyama S; Mikami T; Ohyama C
Int Urol Nephrol; 2022 Jan; 54(1):9-16. PubMed ID: 34714460
[TBL] [Abstract][Full Text] [Related]
13. An Integrative Review of Current Research on the Role of the Female Urinary Microbiota in Overactive Bladder Symptoms.
Angelini KJ
Urol Nurs; 2017; 37(2):94-100. PubMed ID: 29240375
[TBL] [Abstract][Full Text] [Related]
14. The urinary microbiome in patients with refractory urge incontinence and recurrent urinary tract infection.
Chen Z; Phan MD; Bates LJ; Peters KM; Mukerjee C; Moore KH; Schembri MA
Int Urogynecol J; 2018 Dec; 29(12):1775-1782. PubMed ID: 29946828
[TBL] [Abstract][Full Text] [Related]
15. Altered gut microbiome associated with overactive bladder and daily urinary urgency.
Okamoto T; Hatakeyama S; Imai A; Yamamoto H; Yoneyama T; Mori K; Yoneyama T; Hashimoto Y; Nakaji S; Ohyama C
World J Urol; 2021 Mar; 39(3):847-853. PubMed ID: 32419054
[TBL] [Abstract][Full Text] [Related]
16. Diversity of the midstream urine microbiome in adults with chronic kidney disease.
Kramer H; Kuffel G; Thomas-White K; Wolfe AJ; Vellanki K; Leehey DJ; Bansal VK; Brubaker L; Flanigan R; Koval J; Wadhwa A; Zilliox MJ
Int Urol Nephrol; 2018 Jun; 50(6):1123-1130. PubMed ID: 29651696
[TBL] [Abstract][Full Text] [Related]
17. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
18. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
19. The urinary microbiome associated with bladder cancer.
Bučević Popović V; Šitum M; Chow CT; Chan LS; Roje B; Terzić J
Sci Rep; 2018 Aug; 8(1):12157. PubMed ID: 30108246
[TBL] [Abstract][Full Text] [Related]
20. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy.
Liu HT; Lin H; Kuo HC
Neurourol Urodyn; 2011 Nov; 30(8):1525-9. PubMed ID: 21826717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
